Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

Atriva Therapeutics GmbH. (6/30/16). "Press Release: Atriva Therapeutics Completes Transfer of Co-Infection Patent". Tübingen.

Organisations Organisation Atriva Therapeutics GmbH
  Organisation 2 University of Münster (Westfälische Wilhelms-Universität Münster)
Products Product MEK inhibitor
  Product 2 virostatic agent
Person Person Lichtenberger, Rainer (Atriva 201606 CEO + Co-Founder before Cevec + Merckle/ratiopharm + Merck KGaA)

Atriva Therapeutics GmbH announces the acquisition of the co-infection patent (Application Nr: PCT/IB2015/053644) from the University of Muenster, Germany.

This patent covers the beneficial and potentially lifesaving use of MEK inhibitors against co-infections of bacteria, including multi-resistant bacterial strains such as MRSA, which often occurs following a severe influenza viral infection and can be fatal to high-risk influenza patients.

Atriva was founded in 2015 by a leading team of three international key scientists in viral research and seasoned industrial experts, and is located in Tuebingen, Germany. Three patent families that also repurpose MEK inhibitors for antiviral use were transferred during the foundation process, thus shaping Atriva unique business approach.

Atriva product platform is based on a variety of different MEK kinase inhibitors focusing on severe viral infections and applicable for use with high-risk influenza patients.

The market potential is considerable. In total the therapeutic market for acute influenza in high-risk, co-morbidity patients such as those with COPD or heart failure is estimated to exceed 2.8 billion Euros in 2020. As neuraminidase inhibitors are not approved in these patient groups, no suitable or economically labeled therapy is currently available. Without taking into account the preventive pandemic stock-keeping of influenza therapeutics, the potential for net sales of Atriva’s MEK inhibitors could reach 400 million Euros.

Prof. Stephan Ludwig, one of the co-founders of Atriva and co-inventor of the co-infection patent, has grown from his long-term research into one of the world’s key leaders in the field of antiviral therapy. He states: “Acquisition of this key patent is of the utmost importance for the broad protection of the Atriva approach and enhances the scope of our strategies to a broader range of clinically challenging pathogens.”

Dr. Rainer Lichtenberger, co-founder and CEO of Atriva, says: “We are excited to add this ground-breaking patent application to our substantial portfolio of IP that use kinase inhibitors as medicines to fight severe viral respiratory disease. Bacterial co-infections, e.g. with multi-resistant MRSA and other germs remain an ever increasing challenge for the management of influenza and other severe respiratory infections, especially in the 150 million high-risk patients suffering from lung or heart disease in the western world. ”

For further information, please click here or contact:

Dr. Rainer Lichtenberger, phone number +49 7071 8597673, mobile +49 173 743 1897 or e-mail

This document may contain certain forward-looking statements relating to the business, financial performance and results of Atriva Therapeutics GmbH and the industry in which it operates. These statements are based on Atriva’s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words “expect”, “anticipate”, “predict”, “estimate”, “project”, “plan”, “may”, “should”, “would”, “will”, “intend”, “believe” and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements.

Record changed: 2016-11-05


Picture Excelya CRO Your Trial Across Europe 650x80px

More documents for Atriva Therapeutics GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group Global Partnering Four Events One Price 650x80

» top